The U.S. Department of Defense is seeking pre-applications for the following FY17 Spinal Cord Injury Research Program (SCIRP) Awards:
Qualitative Research Award
The intent of the Qualitative Research Award is to support qualitative research studies that will help researchers and clinicians better understand the experiences of individuals with SCI and thereby identify the most effective path(s) for adjusting to disability and/or improving overall quality of life, health, and functional status after SCI. This mechanism is specifically focused on military and Veteran populations in the years after SCI, examining the issues, barriers, and promoters of success for Service members during the transition from initial injury and acute care through rehabilitation and community reintegration; therefore, collaboration with military and VA researchers and clinicians is encouraged. Factors that may affect the rehabilitation and reintegration of spinal cord-injured Service members include, but are not limited to, age, gender, ethnicity, family members/caregivers, psychological health, severity of injury, type of medical care (e.g., civilian, VA, or military facility), and co-morbid conditions. A key feature of the QRA is the inclusion of military and/or Veteran populations in the years after SCI. Applicants should clearly describe how their study design, including recruitment strategies and access to appropriate populations, as applicable, will enable them to meet this intent.
Amount: The anticipated direct costs budgeted for the entire period of performance for an FY17 SCIRP QRA will not exceed $500,000
Translational Research Award
The SCIRP TRA is intended to support translational research that will accelerate the movement
of promising ideas in SCI research into clinical applications. Although not all-inclusive, some
examples include demonstration studies of pharmaceuticals and medical devices in preclinical
systems and/or clinical research on therapeutics, devices, or practice using human tissues or
Amount: The anticipated direct costs budgeted for the entire period of performance for an FY17 SCIRP TRA award will not exceed $1,250,000 for applications without an Optional Qualified
Collaborator, or $1,500,000 for applications with an Optional Qualified Collaborator
Clinical Trial Award
The SCIRP CTA supports research with the potential to have a major impact on the treatment or management of SCI. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other award mechanisms/funding opportunities being offered.
Amount: The anticipated direct costs budgeted for the entire period of performance for an FY17 SCIRP CTA will not exceed $2,000,000
Clinical Research Development Award
The FY17 SCIRP CRDA is intended to support planning and development activities necessary to initiate a future clinical study with the potential to have a significant impact on SCIs. The future study to be developed through the CRDA may be clinical research or a clinical trial (as defined in the full announcement). The FY17 SCIRP CRDA also encourages the inclusion of junior investigators on the research team. Relevance of the research to military and/or Veteran populations affected by SCI is a key element of this award mechanism. Collaboration with military or VA researchers and clinicians is highly encouraged. Inclusion of active duty military or Veteran populations is very highly encouraged. If the research will involve other populations, the relevance to the military or Veteran populations and the rationale for the inclusion of the other populations must be clearly articulated by the applicant. SCIRP CRDA recipients are expected to be ready to apply for advanced funding in the program year following completion of their CRDA and are encouraged to apply for future SCIRP funding through an appropriate FY19 or FY20 SCIRP Program Announcement, if offered.
Amount: The anticipated direct costs budgeted for the entire period of performance for an FY17 SCIRP CRDA will not exceed $100,000
Investigator-Initiated Research Award
IIRA applications may focus on any phase of research from basic through translational. Permitted research includes preclinical studies in animal models, research with human subjects, or human anatomical substances, as well as correlative studies associated with an existing clinical trial. Clinical trials are not allowed under this funding opportunity.
Amount: The anticipated direct costs budgeted for the entire period of performance for an FY17 SCIRP IIRA will not exceed $500,000
Letter of Intent Deadline (for all 5 awards): August 8, 2017
Application submissions accepted by invitation only.